These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 18607264)

  • 1. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
    Papadakis KA; Shaye OA; Vasiliauskas EA; Ippoliti A; Dubinsky MC; Birt J; Paavola J; Lee SK; Price J; Targan SR; Abreu MT
    Am J Gastroenterol; 2005 Jan; 100(1):75-9. PubMed ID: 15654784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
    Riis A; Martinsen TC; Waldum HL; Fossmark R
    Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.
    Swaminath A; Ullman T; Rosen M; Mayer L; Lichtiger S; Abreu MT
    Aliment Pharmacol Ther; 2009 Feb; 29(3):273-8. PubMed ID: 19006540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological therapy in a pediatric Crohn disease population at a referral center.
    Nuti F; Viola F; Civitelli F; Alessandri C; Aloi M; Dilillo A; Del Giudice E; Cucchiara S
    J Pediatr Gastroenterol Nutr; 2014 May; 58(5):582-7. PubMed ID: 24343280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience.
    Oussalah A; Babouri A; Chevaux JB; Stancu L; Trouilloud I; Bensenane M; Boucekkine T; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Feb; 29(4):416-23. PubMed ID: 19035976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
    Russo EA; Iacucci M; Lindsay JO; Campbell S; Hart A; Hamlin J; Orchard T; Arebi N; Nightingale J; Jacyna MR; Gabe SM; O'Connor M; Harris AW; O'Morain C; Ghosh S
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):334-9. PubMed ID: 19528808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
    Hinojosa J; Gomollón F; García S; Bastida G; Cabriada JL; Saro C; Ceballos D; Peñate M; Gassull MA;
    Aliment Pharmacol Ther; 2007 Feb; 25(4):409-18. PubMed ID: 17269996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
    Viola F; Civitelli F; Di Nardo G; Barbato MB; Borrelli O; Oliva S; Conte F; Cucchiara S
    Am J Gastroenterol; 2009 Oct; 104(10):2566-71. PubMed ID: 19550415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab.
    Felipez LM; Gokhale R; Tierney MP; Kirschner BS
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):28-33. PubMed ID: 21681114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term outcome of infliximab therapy in pediatric Crohn disease].
    Wanty C; Stephenne X; Sokal E; Smets F
    Arch Pediatr; 2011 Aug; 18(8):863-9. PubMed ID: 21723101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch.
    Shen B; Remzi FH; Lavery IC; Lopez R; Queener E; Shen L; Goldblum J; Fazio VW
    Aliment Pharmacol Ther; 2009 Mar; 29(5):519-26. PubMed ID: 19183338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.